Targeted Pulse Quiz: July 21

During a Case-Based Roundtable® event, Komal Jhaveri, MD, FACP, discussed dosing and toxicity concerns with the approved CDK4/6 inhibitor regimens used in the adjuvant setting for patients with hormone receptor–positive breast cancer.

In this episode of Targeted Talks, Douglas Flora, MD, LSSBB, FACCC, discusses the transformative impact of artificial intelligence in oncology.

During a Case-Based Roundtable® event, Pierre Gholam, MD, discussed how post hoc and real-world analyses build upon the limited available trial data for treating patients with unresectable hepatocellular carcinoma with Child-Pugh B status.

In this episode of Targeted Talks, Seth Wander, MD, PhD, discusses the clinical importance of ESR1 mutations in HR-positive metastatic breast cancer and how these mutations influence treatment approaches.

MT-303, a novel GPC3-targeting mRNA/lipid nanoparticle chimeric antigen receptor therapy, enhances cytokine-driven immune response and tumor cytotoxicity.

During a Case-Based Roundtable® event, David H. Ilson, MD, PhD, discussed the outcomes of the CheckMate 649, CheckMate 648, and KEYNOTE-859 trials of chemoimmunotherapy regimens in patients with upper GI cancers.